Trospium Chloride XR in Obese Female Patients With Overactive Bladder

Completed · Phase 4 · Has a placebo group

Conditions studied: Obesity, Overactive Bladder, Incontinence

In brief

This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.

Key facts

Study ID

NCT00932022

Run by

Allergan

People needed

127

Starts

2009-07-01

Expected to finish

2011-12-01

Last updated by the study team

2013-01-21

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence
• Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit).
• Obese

You may not qualify if…

• Chronic kidney failure
• Abdominal bypass surgery for obesity
• Moderate or severe memory impairment
• Uncontrolled narrow angle glaucoma
• Uncontrolled systemic disease
• Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia

Where it is running

• Study site — La Mesa, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.